Pareto analyst Filip Wiberg downgraded Xvivo Perfusion (XVIPF) to Hold from Buy with a price target of SEK 500, down from SEK 560. The firm says it is time for the shares to “take a breather.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks